In The News

• Apr 2026

  Denovicon Selected for DOE National Lab Collaboration on Quantum–Photonic Drug Discovery

• Mar 2026

  Denovicon Reports Discovery of DNT-1569: A Highly Potent and Selective Small-Molecule PARP7 Inhibitor for Immuno-Oncology

• Jan 2026

  Denovicon Introduces Quantum Physics-Driven Generative AI For Multi-Objective Optimization of Small-Molecule Drugs

• Nov 2025

  Denovicon Renewed for the 3DEXPERIENCE Lab Accelerator

• Oct 2025

  Denovicon Therapeutics Joins ARPA-H Investor Catalyst Hub Spoke Network

• May 2025

  Re-Inventing Drug Discovery

• Oct 2024

  Denovicon is Accepted into the 3DEXPERIENCE Lab Accelerator

• Apr 2023

  DRUG DISCOVERY CHEMISTRY CONFERENCE 2023